focus -WSS

focus

author：comprehensive 2025-10-02 21:07:07 - browse：58

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Methadone doses haven’t kept up in the age of fentanyl

hotspot

WSS

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Naloxone nonprofit donates 200,000 doses after FDA approval

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Naloxone nonprofit donates 200,000 doses after FDA approval

House GOP plan to stem drug shortages differs from Democrats’

Wikipedia

focus

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

For Cytokinetics, FDA rejection of heart drug would help, not hinder

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why failed clinical trials don’t always spell doom for a new drug

Virginia high school admissions case could be legal follow

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Medical leaders decry Supreme Court decision on affirmative action

In same hospitals, Black patients receive fewer opioids than white patients

hotspot

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

What to know about Virgin Galactic's 1st mission taking paying customers to space

The best solution to the drug shortages problem

American woman, child freed after being kidnapped in Haiti last month

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

hotspot

knowledge

hotspot

Wikipedia